Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 lungcancer-milan.com Hosted by Giuseppe Lo Russo with a world-class faculty

Exploring vulnerability of neoadjuvant/perioperative chemo-ICI in early stage NSCLC. Relative high survival fragility index in 3 trials, censoring imbalance trend in 5 trials. Poster 1232P Antonio Nuccio Fabio Salomone giuseppe viscardi Università Vita-Salute San Raffaele #ESMO2024

a deep look into the dark side of immunotherapy through clinical and radiological biomarkers of progression. inspiring Roberto Ferrara at #ESMO2024

as oncologists in the middle-hearth thanks to the chair of "empowering supportive care in thoracic cancers" @raffaelegiusti and Daniele Marinelli for his impactful representation

Session on targeted therapy chaired by Drs. Rita Leporati giuseppe viscardi Claudia Proto with Luis Paz-Ares discussing #EGFR: FLAURA2 vs MARIPOSA - longer PFS but cost of toxicity & infusions. Many prognostic factors, need predictive ones. Ivonescimab - is this the future of IO for EGFR?

Dr. Roberto Ferrara delivers a brilliant summary of #NTRK #RET and #MET NSCLC. Important point on RET is trial demographics vs real world (inc histology), which impacts outcomes. Multiple targeted agents available for all of these but resistance still a challenge. #ILCS24

Excited to share our new perspective in #ESMORWD, "Oncology Education in the Age of Artificial Intelligence. we advocate that AI literacy has become a relevant skill x oncologists sciencedirect.com/science/articl… thanks to the co-authors Giovanni Scoazec Dyke Ferber and my friend Jakob Nikolas Kather ESMO - Eur. Oncology

Perioperative not better than neoadjuvant ICI in both pCR and non-pCR NSCLC. Postoperative ICI must be tailored in a curative setting to reduce potential tox and treatment burden. Data on MPR are coming. Antonio Nuccio Daniele Marinelli giuseppe viscardi jto.org/article/S1556-…

"AI literacy" for next-generation oncologists

☑️ pCR (and MPR) as reliable predictors of EFS after neoadjuvant CT-ICI in NSCLC ➡️ Need for additional biomarkers to personalize post-operative strategy Daniele Marinelli Kakhadze Olga Roberto Ferrara Antonio Nuccio jto.org/article/S1556-…

69.3% five-year survival rate in stage IIIA NSCLC with perioperative chemo-immunotherapy is the new milestone thelancet.com/journals/lanon…

An example of how a strong and well-prepared multidisciplinary team can achieve incredible results!

Facing complexity in stage III NSCLC One size doesn't fit for all: personalization, multimodality and multidisciplinarity are required Marcello Tiseo AIOM_Campania AIOM

Young oncologists Campania Team 💫 at the AIOM games! A thrilling challenge among Southern 🇮🇹 regions #AIOMgiovani. Together we stand stronger! 💪🏻 AIOM_Campania giuseppe viscardi

2024: Fortunately is difficult to merge all ttx for NSCLC 🫁 in 1 slide. Hwv, still pending: ✏️avoid “me too” approvals if prices not ⬇️ ✏️ consol TKI for all and for lifetime? ✏️⬆️genotyping access & drug access ✏️➕ academic trials of de-escalating ✏️periop vs neoadj@OncoAlert

Proud to announce the creation of the European Interdisciplinary Society for AI in Cancer Research EU Interdisc. Society of AI for Cancer Research is here to advance AI focus on the multidisciplinarity necessary to, effectively implement AI in Cancer Research stellar Steering Committee ! #AIinCancer Jakob Nikolas Kather

Out in The Cochrane Library our metanalysis on adj EGFR TKIs for EGFRm NSCLC doi.org/10.1002/146518… 🆚 TKI vs pbo: DFS↑ (HR 0.41), recurrences ↑post-TKI 🆚 TKI vs CT: DFS↑ (HR 0.47), OS unclear 💡Role of adj CT ❓Optimal TKI duration Roberto Ferrara Mario Occhipinti

Can we spare adj chemo in resected EGFR NSCLC? Probably no. Our Cochrane metanalysis shows no OS difference with 1st/2nd gen EGFR TKI vs adj chemo. Relapses during the EGFR TKIs drug off time were higher compared to adj chemo (45% vs 30%). Cochrane cochranelibrary.com/cdsr/doi/10.10…

Just published in BMJ Oncology the report of AIOM national conference about patient-reported outcomes in clinical trials and clinical practice. A relevant step in the awareness and scientific debate about these topics. Many thanks to all coauthors! bmjoncology.bmj.com/content/4/1/e0…

This is my will and my final message. If these words reach you, know that Israel has succeeded in killing me and silencing my voice. First, peace be upon you and Allah’s mercy and blessings. Allah knows I gave every effort and all my strength to be a support and a voice for my